Violetta Hughes
REPLIGENAbout Violetta Hughes
Violetta Hughes, age 53, was appointed Chief Accounting Officer (principal accounting officer) of Repligen Corporation effective September 1, 2025; she signed the company’s Q3 2025 Form 10‑Q as CAO on November 4, 2025 . She holds a B.S. in Accounting from the University of Massachusetts Lowell and brings 25+ years of controllership, SOX compliance, and financial governance experience across life sciences and pharma . Repligen’s executive incentive framework emphasizes adjusted revenue and adjusted EPS for annual cash incentives; this provides a clear line-of-sight between finance leadership and performance outcomes . Company operating context over the last four quarters is shown below.
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 |
|---|---|---|---|---|
| Revenue ($USD) | $167,547,000 | $169,172,000 | $182,366,000 | $188,805,000 |
| EBITDA ($USD) | $49,081,000* | $28,155,000* | $29,700,000* | $32,686,000* |
Values retrieved from S&P Global.*
Past Roles
| Organization | Role | Years | Strategic Impact |
|---|---|---|---|
| Azenta, Inc. (NASDAQ: AZTA) | VP & Chief Accounting Officer | Jan 2023 – Aug 2025 | Modernized financial systems, streamlined close, improved SOX compliance |
| Akebia Therapeutics (NASDAQ: AKBA) | SVP & Chief Accounting Officer | Dec 2020 – Dec 2022 | Led controllership and SOX frameworks |
| AMAG Pharmaceuticals | SVP Accounting, Corporate Controller | Dec 2016 – Nov 2020 | Public company controllership; pre-acquisition by Covis Pharma |
External Roles
| Organization | Role | Years | Notes |
|---|---|---|---|
| — | — | — | No public company directorships or external board roles disclosed in SEC filings |
Fixed Compensation
| Component | Value | Effective Date | Notes |
|---|---|---|---|
| Base Salary | $395,000 | Sep 1, 2025 | Approved by Compensation Committee |
| Signing Bonus | $150,000 | Sep 1, 2025 | One‑time sign‑on |
| Target Annual Bonus | Up to 50% of base | Sep 1, 2025 | Annual cash incentive eligibility |
| Benefits | Customary employee plans | Sep 1, 2025 | Eligible for plans generally available to full‑time employees |
Performance Compensation
Annual Incentive Plan (Company Framework for NEOs)
| Metric | Weighting | Target | Actual | Payout Mechanics | Notes |
|---|---|---|---|---|---|
| Adjusted Revenue | 50% of Company Objectives (equal weight vs EPS) | $630.0M (2024) | $634.8M (2024 adjusted) | 0% below 90%; 100% at target; 200% at ≥120% | NEOs other than CEO/Executive Chair: Company Objectives 75% / Individual Objectives 25% |
| Adjusted EPS | 50% of Company Objectives (equal weight vs revenue) | $1.50 (2024) | — | 0% at ≤70%; 100% at target; 200% at ≥130% | CEO/Executive Chair payout solely on Company Objectives |
Note: Ms. Hughes’ 2025 individual metrics and payout not disclosed; her plan target bonus is 50% of base .
Equity Awards (Grant Mechanics and Vesting)
| Instrument | Grant/Filing Date | Shares/Units | Fair Value / Strike | Vesting | Expiration |
|---|---|---|---|---|---|
| RSUs | Sep 2, 2025 | 4,142 | Grant per Form 4 | Equal annual installments on 1st–5th anniversaries of Sep 1, 2025 (i.e., 9/1/2026–9/1/2030) | |
| Stock Options | Sep 2, 2025 | 3,914 | $120.69 strike | Equal annual installments on 1st–5th anniversaries of Sep 1, 2025 (i.e., 9/1/2026–9/1/2030) | Not disclosed |
Company disclosed an annual equity award framework totaling $750,000 (approx. $500,000 RSUs; $250,000 options) effective as of the appointment date, subject to Compensation Committee approval and five-year equal annual vesting . The Form 4 aligns with that framework .
Equity Ownership & Alignment
| Category | Detail |
|---|---|
| Beneficial Ownership at Appointment | Form 3 filed Sept 4, 2025 states “No securities are beneficially owned.” |
| Initial Grants | 4,142 RSUs and options for 3,914 shares at $120.69 strike on Sep 2, 2025; five-year equal annual vesting |
| Vested vs Unvested | Entire Sep 2025 RSU/option grants unvested until first vest date (9/1/2026) |
| Hedging/Pledging | Not permitted for executive officers; anti-hedging/anti-pledging and anti-short sale policies in place |
| Ownership Guidelines | CEO: 5x salary; NEOs (other than CEO): 1x salary; five-year compliance window; RSUs counted, options/PSUs excluded |
| Compliance Status | All directors and NEOs comply or are on track within five years (role-specific applicability depends on NEO designation) |
Employment Terms
| Term | Detail |
|---|---|
| Role/Start | Chief Accounting Officer; principal accounting officer effective Sep 1, 2025 |
| Compensation | $395,000 base; $150,000 sign-on; target annual bonus up to 50% of base |
| Equity | Annual award aggregating $750,000 (approx. $500,000 RSUs; $250,000 options), five-year equal annual vesting |
| Severance | Not disclosed for Ms. Hughes in public filings reviewed |
| Change of Control | Not disclosed for Ms. Hughes; company Severance Plan applies to certain NEOs with double-trigger provisions; details provided for other executives in proxy |
| Clawback | Compensation Recovery Policy adopted Oct 2023; three-year lookback for executive officers upon restatement |
| Related Party | No arrangements/understandings, family relationships, or related party transactions per 8‑K |
| Insider Trading Policy | Pre-approval required for certain derivative/hedging/pledging transactions; gifts restricted during blackout; policy filed with 10‑K exhibits |
Investment Implications
- Retention and selling pressure: Five-year equal annual vesting on RSUs/options with first vest on 9/1/2026 suggests strong retention incentives and limited near-term selling pressure; monitor Form 4 filings around annual vest dates for tax withholding or net share settlements .
- Alignment safeguards: Anti-hedging/anti-pledging policies, stock ownership guidelines (NEO framework), and a Dodd-Frank compliant clawback reduce agency risk and support compensation discipline .
- Pay-for-performance structure: Repligen’s AIP ties payouts to adjusted revenue and adjusted EPS with thresholds/caps, reinforcing financial rigor—a positive backdrop for a principal accounting officer overseeing controls and reporting .
- Execution risk and value creation: Appointment focused on strengthening SOX and reporting infrastructure; near-term KPI improvements should be evaluated in context of revenue/EBITDA trends and any internal control disclosures—she is already co-signatory on Q3 2025 10‑Q .
- Watch items: Lack of disclosed individual severance/CIC terms for Ms. Hughes (versus detailed plans for other NEOs) leaves some retention economics opaque; track future proxy updates and 8‑K 5.02 filings for any amendments .